Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T cell therapy received approval from China’s National Medical Products Administration on June 22, 2021, it is the first approved CAR T cell therapy product in China.
The innovative CAR T cell therapy from Fosun Kite Biotechnology is approved as a second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
The product will soon be available in hospitals in China.
Apart from Yescarta, numbers of CAR T cell therapy from international and domestic pharmaceutical giants are in clinical trials.
